To the best of our knowledge, this is the first reported case of the efficacy of this combination therapy in a patient with BRAF Class I alterations, which occur at the V600 codon and exhibit extremely strong kinase activity by stimulating monomeric activation of BRAF in prostate cancer (27). This evidence concerns the gene BRAF and prostate cancer.